Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study
PURPOSE: Gonadotropin-releasing hormone (GnRH) analogues reduce testosterone levels to castration levels in patients with prostate cancer. However, the role of testosterone in atopic diseases has remained undefined. We aimed to investigate this role. MATERIALS AND METHODS: This retrospective cohort...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000094/ https://www.ncbi.nlm.nih.gov/pubmed/35404960 http://dx.doi.org/10.1371/journal.pone.0266771 |
_version_ | 1784685349806538752 |
---|---|
author | Lin, Sheng-Feng Lin, Hsiu-Chen Lee, Mei-Yu Keller, Joseph Jordan Wang, Li-Hsuan |
author_facet | Lin, Sheng-Feng Lin, Hsiu-Chen Lee, Mei-Yu Keller, Joseph Jordan Wang, Li-Hsuan |
author_sort | Lin, Sheng-Feng |
collection | PubMed |
description | PURPOSE: Gonadotropin-releasing hormone (GnRH) analogues reduce testosterone levels to castration levels in patients with prostate cancer. However, the role of testosterone in atopic diseases has remained undefined. We aimed to investigate this role. MATERIALS AND METHODS: This retrospective cohort study was conducted using the National Health Insurance Research Database (NHIRD). Patients with prostate cancer were categorized into two groups according to whether they received GnRH analogue treatment (study group I) or not (study group II), and men without prostate cancer and with no GnRH analogue use were defined to comprise the comparison group after their ages and index years were matched with group II. Cox proportional hazard models were used to assess the hazard ratio (HR) of atopic diseases. RESULTS: Group I, group II, and the comparison group comprised 663, 2,172, and 8,688 individuals, respectively. Group I had a significantly lower risk of atopic diseases (adjusted HR: 0.66, 95% CI, 0.49–0.89, p < 0.01) than did group II. A reduced risk of atopic diseases was found when GnRH analogues were prescribed for 2 months (adjusted HR 0.53, 95% CI, 0.29–0.97, p = 0.04) and 2–14 months (adjusted HR 0.66, 95% CI, 0.49–0.89, p = 0.007). No significant difference in the risk of atopic diseases between group II and the comparison group was observed. CONCLUSIONS: A decreased risk of atopic diseases was observed in patients with prostate cancer treated with GnRH analogues. Further studies are warranted to verify the association between testosterone levels and atopic diseases. |
format | Online Article Text |
id | pubmed-9000094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-90000942022-04-12 Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study Lin, Sheng-Feng Lin, Hsiu-Chen Lee, Mei-Yu Keller, Joseph Jordan Wang, Li-Hsuan PLoS One Research Article PURPOSE: Gonadotropin-releasing hormone (GnRH) analogues reduce testosterone levels to castration levels in patients with prostate cancer. However, the role of testosterone in atopic diseases has remained undefined. We aimed to investigate this role. MATERIALS AND METHODS: This retrospective cohort study was conducted using the National Health Insurance Research Database (NHIRD). Patients with prostate cancer were categorized into two groups according to whether they received GnRH analogue treatment (study group I) or not (study group II), and men without prostate cancer and with no GnRH analogue use were defined to comprise the comparison group after their ages and index years were matched with group II. Cox proportional hazard models were used to assess the hazard ratio (HR) of atopic diseases. RESULTS: Group I, group II, and the comparison group comprised 663, 2,172, and 8,688 individuals, respectively. Group I had a significantly lower risk of atopic diseases (adjusted HR: 0.66, 95% CI, 0.49–0.89, p < 0.01) than did group II. A reduced risk of atopic diseases was found when GnRH analogues were prescribed for 2 months (adjusted HR 0.53, 95% CI, 0.29–0.97, p = 0.04) and 2–14 months (adjusted HR 0.66, 95% CI, 0.49–0.89, p = 0.007). No significant difference in the risk of atopic diseases between group II and the comparison group was observed. CONCLUSIONS: A decreased risk of atopic diseases was observed in patients with prostate cancer treated with GnRH analogues. Further studies are warranted to verify the association between testosterone levels and atopic diseases. Public Library of Science 2022-04-11 /pmc/articles/PMC9000094/ /pubmed/35404960 http://dx.doi.org/10.1371/journal.pone.0266771 Text en © 2022 Lin et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Lin, Sheng-Feng Lin, Hsiu-Chen Lee, Mei-Yu Keller, Joseph Jordan Wang, Li-Hsuan Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study |
title | Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study |
title_full | Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study |
title_fullStr | Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study |
title_full_unstemmed | Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study |
title_short | Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study |
title_sort | association between gnrh analogue use and atopic diseases in patients with prostate cancer: a population-based retrospective cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000094/ https://www.ncbi.nlm.nih.gov/pubmed/35404960 http://dx.doi.org/10.1371/journal.pone.0266771 |
work_keys_str_mv | AT linshengfeng associationbetweengnrhanalogueuseandatopicdiseasesinpatientswithprostatecancerapopulationbasedretrospectivecohortstudy AT linhsiuchen associationbetweengnrhanalogueuseandatopicdiseasesinpatientswithprostatecancerapopulationbasedretrospectivecohortstudy AT leemeiyu associationbetweengnrhanalogueuseandatopicdiseasesinpatientswithprostatecancerapopulationbasedretrospectivecohortstudy AT kellerjosephjordan associationbetweengnrhanalogueuseandatopicdiseasesinpatientswithprostatecancerapopulationbasedretrospectivecohortstudy AT wanglihsuan associationbetweengnrhanalogueuseandatopicdiseasesinpatientswithprostatecancerapopulationbasedretrospectivecohortstudy |